NEU neuren pharmaceuticals limited

Dividend reinvestment plan for Neu, page-7

  1. 300 Posts.
    lightbulb Created with Sketch. 94
    High level thoughts from me as a fossil long termer:

    Pros:
    - shows intent to benefit shareholders
    - shows confidence in a buy out (ie not needing the cash)
    - shareholders can ‘get something’ while we wait (yes, arguably same as point one)

    Cons:
    - generally increases shares on issue, when buy back has just had opposite impact (but arguably in safer hands? Not sure…)
    - less cash to advance other trials should it be needed
    - arguably more vulnerable position re corporate action due to point above (ie less premium as it arguably restricts our ability to go it alone)
    - don’t think it would be on Jon’s radar as my reading between the lines is he doesn’t think we are a dividend company (yet)

    In summary, as a holder I would probably welcome it but it would make me question more the future viability and basically the longer we go without a takeover offer the more I would be questioning our ability to attract one.

    I agree we have not been meeting committed timelines and this needs to be first priority. This is unusual for Jon and I for one hope there is a very good reason.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$15.75
Change
0.580(3.82%)
Mkt cap ! $1.960B
Open High Low Value Volume
$15.35 $15.92 $15.24 $8.664M 553.6K

Buyers (Bids)

No. Vol. Price($)
1 2000 $15.72
 

Sellers (Offers)

Price($) Vol. No.
$15.79 1471 2
View Market Depth
Last trade - 16.13pm 22/07/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.